SynthesisFrontiers in immunology2026
Building bridges to immunotherapy: a knowledge-mapping analysis of cervical cancer organoid research.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer, a human papillomavirus (HPV) -driven malignancy with inherent viral antigenicity, serves as a key model in immuno-oncology. Yet, the variable efficacy of immune checkpoint inhibitors highlights a critical gap: the lack of preclinical models that accurately mirror the patient-specific tumor microenvironment (TME). Patient-derived organoids (PDOs) offer a transformative solution, preserving autologous tumor and immune components for personalized therapeutic testing. This study provides the first bibliometric analysis of this evolving field, mapping its knowledge structure from model development to immuno-oncological application. By analyzing 130 publications (1992-2025) from Web of Science, PubMed, and Scopus using VOSviewer and CiteSpace, we delineate a clear, three-stage evolution: from foundational HPV virology and culture techniques, through pivotal organoid methodology establishment (e.g., Burk RD, 2017), to the current translational phase. This progression is marked by citation bursts in TME modeling (e.g., Lohmussaar K, 2021) and the emergence of keywords like "drug screening" and "immunotherapy". Research is dominated by the U.S., China, and European nations, published within an interdisciplinary core of oncology, immunology, and virology journals. Our analysis highlights the role of organoids as a crucial bridge linking basic virology to clinical immuno-oncology. However, standardization hurdles and suboptimal establishment rates for certain subtypes impede clinical translation. To realize the full potential of PDOs, future work must prioritize standardized immune-competent co-culture systems, integrate AI for high-content data analysis, and promote equitable global collaborations. Our analysis suggests the role of organoids as a crucial bridge linking basic virology to clinical immuno-oncology, highlighting that current advancements in tumor microenvironment modeling are establishing the necessary foundation for future immunotherapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.